Pipeline
Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.
Therapy |
Product |
Indication |
Cell |
Development |
Pre-clinical |
Phase I |
Phase II |
Phase III |
Market Introduction |
Partner |
|---|---|---|---|---|---|---|---|---|---|---|
GTA002 |
Acute Myeloid Leukemia / Multiple Myeloma |
NK cell |
color |
color |
color |
color |
2nd half 2023 |
US: Glycostem; EU: Glycostem; JP: inno.N; KR: inno.N |
||
GTA002 |
Solid Tumors |
NK cell |
color |
color |
TBA |
Glycostem |
Therapy |
Product |
Cell |
Indication |
Development |
Pre-clinical |
Phase I |
Phase II |
Phase III |
Market introduction |
Partner |
|---|---|---|---|---|---|---|---|---|---|---|
GTA102 |
CAR-NK |
Bowel cancer |
color |
color |
TBA |
Glycostem |
||||
GTA103 |
CAR-NK |
Glioblastoma |
color |
color |
TBA |
inno.N |
||||
GTA104 |
CAR-NK |
N/D |
color |
color |
TBA |
inno.N |
||||
GTA105 |
Combination therapy |
N/D |
color |
TBA |
Glycostem |
|||||
GTA201 |
TCR-NK |
N/A |
color |
TBA |
Glycostem |